Navigation Links
Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
Date:1/23/2008

CHESTER, N.J., Jan. 23 /PRNewswire/ -- Molecular Biometrics, a privately-held company developing novel diagnostic tools to more accurately characterize biologic function in health and disease, today announced that Denny Sakkas, Ph.D., Associate Professor, Yale University School of Medicine, and Director of the embryology laboratory at Yale Fertility Center, has joined the company as Chief Scientific Officer. Molecular Biometrics is applying its proprietary metabolomics technology to bring new accuracy to diagnostics in five areas of medicine where there is a demonstrated need, including reproductive health, neurodegenerative disease (Alzheimer's disease and Parkinson's disease), maternal fetal medicine, and drug discovery and development. The company's lead product candidates are diagnostic tests used to evaluate embryos, oocytes and sperm viability for in vitro fertilization (IVF).

Molecular Biometrics also announced that it is opening a new 2,200 square foot research facility, adjacent to Yale University, in January 2008. Dr. Sakkas will oversee the company's research and development activities from this new lab facility, which will initially be dedicated to the company's lead product candidate, ViaTest-E(TM). ViaTest-E is in late-stage development for the assessment of embryo viability in the field of IVF and assisted reproductive technology.

"Dr. Sakkas brings decades of research and clinical experience to our team. Denny is one of the top scientists in the field of embryology and has pioneered embryo culture, diagnosis and selection techniques, the analysis of cells to detect disease, and the development of tests for genetic disorders and chromosomal abnormalities," said James T. Posillico, PhD, President and Chief Executive Officer, Molecular Biometrics. "Denny will take on an integral role working with the company's scientific team to develop metabolomic-based diagnostic tools that offer more accurate, non-invasive methods for the embryology laboratory that will ultimately improve outcomes in IVF." Dr. Sakkas has been a member of Molecular Biometrics' Scientific Advisory Board since the inception of the company.

Dr. Sakkas received his undergraduate training at the University of Melbourne, Australia, and his Doctorate of Philosophy at Monash University, Melbourne. Prior to joining the Yale Fertility Center, he had been the laboratory director at major IVF centers in Switzerland, England and the United States.

Dr. Sakkas is internationally recognized for his work in reproductive health research, has published more than 100 manuscripts and chapters in the fields of fertilization, early embryo development and male infertility, and serves on the editorial board of several leading scientific journals in the field.

Metabolomics at Molecular Biometrics

Molecular Biometrics is developing novel diagnostics based on metabolic profiles comprised of known biologic and chemical markers for disease and normal functioning, a science known as metabolomics. The company is applying its patented application of biospectroscopy -- light analysis technology -- and bioinformatics to develop diagnostic tools in five areas of medicine.

Metabolomics is a complex scientific process that can identify and measure individual signals from many small molecular compounds produced by cellular metabolism which, when evaluated as a whole, represent unique biomarkers of normal biologic function in health and disease.

Near infrared (NIR) biospectroscopy, when applied with metabolomic analysis, evaluates the absorption of light specific to small molecule functional groups, to create a biomarker profile of molecules that are descriptive of cellular function and viability. The result is the creation of a novel "metabolomic profile" or "fingerprint."

Metabolomic profiling is used to systematically distinguish between the often subtle differences that separate normal physiology from the onset or progression of disease, or an individual's response to therapeutic intervention. Metabolomics is commonly used in pharmaceutical research, medical diagnostics, and food and agrichemical industries.

Molecular Biometrics is applying metabolomics in the development of diagnostic tools in the areas of infertility (to determine viability of embryos, sperm and oocytes used in IVF), maternal fetal medicine (to monitor the health status of a growing fetus, in-utero), and for the early diagnosis of neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.

About Molecular Biometrics

Molecular Biometrics, LLC, is headquartered in Chester, NJ, with research and development facilities in Montreal, Quebec, and New Haven, CT. The company is applying novel metabolomic technologies to develop accurate, non-invasive diagnostic tools for use in evaluating normal biologic function in health and disease, and for drug discovery and development. The company's proprietary technology is being applied in reproductive health and IVF, neurodegenerative disease (Alzheimer's disease and Parkinson's disease), maternal fetal medicine, pulmonary metabolism and edema, and lactate metabolism. For more information, please visit http://www.molecularbiometrics.com.


'/>"/>
SOURCE Molecular Biometrics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
3. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
4. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
5. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
10. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
(Date:2/17/2017)... Plantation, FL (PRWEB) , ... February 17, 2017 ... ... protection services and financial planning assistance to families and business owners in the ... the LifeNet 4 Families organization. , For more than 30 years, LifeNet ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is ... ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An initiative ... ACE.P will address what has been identified as a critical gap in preparing the ...
(Date:2/16/2017)... , ... February 16, 2017 , ... ... highly regarded orthopedic surgeon, Dr. Raj, to their network through his work at ... Chemistry from Dalhousie University, and his medical degree from Canada’s prestigious International Baccalaureate ...
Breaking Medicine News(10 mins):